Koike Ryuji, Harigai Masayoshi
Clinical Research Center, Tokyo Medical and Dental University.
Nihon Rinsho. 2007 Jul;65(7):1314-20.
Pneumonia (almost equally bacterial) is the most common and serious adverse events of the patients with rheumatoid arthritis (RA) prescribing anti-tumor necrosis factor(TNF) agents. Furthermore, it has been shown that Pneumocystis jirovecii should be one of the important causal microorganisms by the results of postparketing all-patients registration surveillance in Japan. Older age, pulmonary comorbidities, diabetes mellitus, or dosage of co -prescribing glucocorticoid has been extracted as a predictable risk factor respectively and synergistically by the surveillance. When prescribing anti-TNF agents, it is possible that considering these risk factors might reduce the incidence of bacterial or Pneumocystis pneumonia in RA patients.
肺炎(几乎同样常见的是细菌性肺炎)是类风湿关节炎(RA)患者使用抗肿瘤坏死因子(TNF)药物时最常见且严重的不良事件。此外,日本上市后全患者登记监测结果表明,耶氏肺孢子菌应是重要的致病微生物之一。监测分别并协同提取出年龄较大、肺部合并症、糖尿病或联合使用糖皮质激素的剂量作为可预测的风险因素。在开具抗TNF药物处方时,考虑这些风险因素可能会降低RA患者细菌性或肺孢子菌肺炎的发病率。